Navigation Links
ESMO 2012 Congress: Program preview
Date:9/4/2012

The final program of the ESMO 2012 Congress including all late-breaking abstract titles is online! http://www.esmo.org/events/vienna-2012-congress/program.html

The ESMO 2012 Congress looks to be one of the best in this year's oncology scenario, possibly a "practice-changing" congress: results from long awaited trials; new drug approvals or new indications for drugs already used in other settings; randomized phase III studies and trials in earlier phases of research, which indicate new signals of activity or bring new concepts for future research; also studies that seem disappointing if you simply look at numbers, but with beautiful scientific rationale, for which expert and lively discussions are expected on how to move on with research agenda priorities or in the practice arena upon non-validation of the original hypothesis

Watch out for thrilling results in the following areas and make sure you don't miss the expert discussions on the future of treatments for these diseases:

  • Lung cancer: crizotinib, a new ready-to-use targeted drug for a molecularly defined sub-set of patients based on the results of the first phase III study in such setting; study results offering for the first time directions on how to treat patients with a certain EGFR mutation; first-time positive results for sorafenib treatment based on biomarker analysis in heavily pre-treated patients
  • Renal cell carcinoma: new drug in the jungle of available treatments for RCC; different strategies to target the disease
  • Melanoma: combination of MEK and BRAF inhibitors proves clinically meaningful to delay resistance
  • Early and metastatic breast cancer: answers on standard duration of adjuvant treatment for HER2-positive early breast cancer; what's behind low breast conserving surgery in the context of clinical trials;
  • Gastrointestinal tumors: what could be the role of targeted treatments for esophageal cancer progressing after chemo; combination of therapies for gastric cancer in a specific ethnicity; new targets and results of clinical studies with targeted agents in hepatocellular carcinoma
  • CNS tumors: new predictive marker identified for anti-angiogenic treatment
  • Ovarian cancer: drug combination opportunity for platinum-resistant recurrent ovarian cancer
  • Sarcoma: awaited results of a long-term academic study evaluating classical chemotherapy agents in a fashion of single versus combination first-line treatment for advanced soft tissue sarcoma

    Just to mention a few

    Not to be missed are also presentations and discussions on:

  • The economic direct and indirect burden of cancer in Europe
  • Health economics and drug cost in austerity
  • Patient awareness and understanding of personalized medicine
  • General public and oncology professional poor knowledge of risk factors for cancer
  • The need for prophylaxis of thrombosis in cancer patients
  • Future models of independent clinical research
  • Accessibility of cancer pain killers
  • Hereditary cancers and screening protocols Read the interview with Dr Judith Balmana, Chair of the ESMO 2012 Familial cancer track] http://www.esmo.org/fileadmin/media/pdf/2012/events/vienna/press/Balmana_FamilialCancers.pdf

    ESMO 2012 Press timetable

    These and other interesting topics will be presented during special sessions for the media. The full text of the abstracts will be published on Monday, September 17 at 9:00 (CEST). Late-breaking abstracts and abstracts included in the press program will remain embargoed until their presentation at the Congress session or at the Press briefing, whichever comes first.

    Wednesday, 26 September, 10:00-11:00, Presseclub Concordia
    German Press Conference: Congress program highlights with specific reference to topics for the Austrian media. Featuring a.o. the Austrian Minister of Health

    Friday, 28 September, 11:30-12:30, ESMO Press Conference Room, ACV
    Opening press conference: ESMO's President welcome; Congress program highlights; Appointments for journalists; The economic direct and indirect burden of cancer in Europe

    Saturday, 29 September, 8:15-9:00, ESMO Press Conference Room, ACV
    Press briefing Day 1: Melanoma; Lung cancer; Gastrointestinal tumors

    Saturday, 29 September, 11:00-12:00 (TBC), ESMO Press Conference Room, ACV
    Press conference: What personalized medicine practically means for patients

    Sunday, 30 September, 8:15-9:00, ESMO Press Conference Room, ACV
    Press briefing Day 2: Breast cancer; Lung cancer; Promising new weapons in the fight against cancer

    Sunday, 30 September, 12:00-13:00, ESMO Press Conference Room, ACV
    Press Conference: Prevention and screening What people know about it

    Monday, 1 October, 8:15-9:00, ESMO Press Conference Room, ACV
    Press briefing Day 3: Breast cancer; Renal cell carcinoma; Gastrointestinal tumors

    Tuesday, 2 October, 9:30-10:30, ESMO Press Conference Room, ACV
    Closing press conference: Congress highlights; Top practice changes to make after ESMO 2012; Cancer care in austerity times: how to improve equal access to quality cancer care across Europe


    '/>"/>


  • Contact: Vanessa Pavinato
    media@esmo.org
    European Society for Medical Oncology
    Source:Eurekalert

    Related medicine news :

    1. Wayne State researchers say adolescent smoking prevention programs still critical
    2. Germany launches a €16 million epigenome program
    3. Cleveland Clinic Florida receives approval for transplant programs at Weston Facilities
    4. Adolescents in substance abuse programs report using others med marijuana
    5. Implementing a therapeutic hypothermia program for post-cardiac arrest in acute care hospitals
    6. New FDA program adds to tools to curb opiod abuse in United States
    7. Surgical patient safety program lowers SSIs by one-third following colorectal operations
    8. ASH launches multi-million-dollar grant program to support critical blood disease research
    9. A nursing program shows promise for reducing deaths from chronic illnesses
    10. Scientists find new way to induce programmed cell death, or apoptosis
    11. Gallo Research Center to lead $15 million US Army-funded national research program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/30/2016)... Indianapolis, Indiana (PRWEB) , ... April 30, 2016 , ... ... USA Wrestling as they go for gold in Rio. Under the care of ... including two golds! , In an unprecedented showing, Maximized Living is sending the largest ...
    (Date:4/29/2016)... ... April 29, 2016 , ... ... the Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation ... the first accreditation of three residency programs that Memorial is currently pursuing, including ...
    (Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
    (Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a ... proud to announce one of their physicians has been invited to be a featured ... ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. Scott ...
    (Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
    Breaking Medicine News(10 mins):
    (Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
    (Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
    (Date:4/28/2016)... 28, 2016 New market ... is a report that provides an overview of ... pipelines by identifying new targets and MOAs to ... Profiles discussed in this H1 2016 Osteoarthritis Pipeline ... AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios ...
    Breaking Medicine Technology: